ATE525081T1 - Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit - Google Patents

Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit

Info

Publication number
ATE525081T1
ATE525081T1 AT03711550T AT03711550T ATE525081T1 AT E525081 T1 ATE525081 T1 AT E525081T1 AT 03711550 T AT03711550 T AT 03711550T AT 03711550 T AT03711550 T AT 03711550T AT E525081 T1 ATE525081 T1 AT E525081T1
Authority
AT
Austria
Prior art keywords
upa
tpa
urokinase
peptides
regulating
Prior art date
Application number
AT03711550T
Other languages
English (en)
Inventor
Abd-Al-Roof Higazi
Original Assignee
Thrombotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/020077 external-priority patent/WO2003006042A1/en
Application filed by Thrombotech Ltd filed Critical Thrombotech Ltd
Application granted granted Critical
Publication of ATE525081T1 publication Critical patent/ATE525081T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03711550T 2002-05-08 2003-03-12 Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit ATE525081T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/063,046 US20030211095A1 (en) 2002-05-08 2002-05-08 Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
PCT/US2002/020077 WO2003006042A1 (en) 2001-07-10 2002-06-24 Peptide for regulation of tissue plasminogen activator
PCT/US2003/007683 WO2003095476A2 (en) 2002-05-08 2003-03-12 PEPTIDES FOR REGULATION OF UROKINASE (uPA) AND TISSUE TYPE (tPA) PLASMINOGEN ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY

Publications (1)

Publication Number Publication Date
ATE525081T1 true ATE525081T1 (de) 2011-10-15

Family

ID=29399060

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03711550T ATE525081T1 (de) 2002-05-08 2003-03-12 Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit

Country Status (10)

Country Link
US (1) US20030211095A1 (de)
EP (1) EP1507547B1 (de)
JP (1) JP2006502096A (de)
AT (1) ATE525081T1 (de)
AU (1) AU2003213856B2 (de)
CA (1) CA2488968C (de)
DK (1) DK1507547T3 (de)
ES (1) ES2373713T3 (de)
IL (1) IL165066A (de)
WO (1) WO2003095476A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263351A1 (en) * 2002-12-31 2006-11-23 The General Hospital Corporation Methods and compositions for protection against thrombolysis associated reperfusion injury
JP5421257B2 (ja) * 2007-07-24 2014-02-19 ディー−ファーム リミテッド プラスミノーゲン活性化因子阻害物質１由来のペプチドおよびその使用
KR101712208B1 (ko) 2008-01-09 2017-03-03 인트렉손 코포레이션 Ｐａｉ―１ 작용의 치료학적 억제제 및 이의 사용 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558010A (en) * 1980-04-03 1985-12-10 Abbott Laboratories Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom
US5236704A (en) * 1988-01-28 1993-08-17 Sumitomo Pharmaceuticals Co., Ltd. Controlled release formulation
US5130143A (en) * 1988-11-04 1992-07-14 The Research Foundation Of State University Of New York Use of a low affinity-heparin fraction in conjunction with t-pa for thrombolytic therapy
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US6150332A (en) * 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
AU739373B2 (en) * 1997-10-17 2001-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
WO2003006042A1 (en) * 2001-07-10 2003-01-23 Thrombotech Ltd. Peptide for regulation of tissue plasminogen activator

Also Published As

Publication number Publication date
AU2003213856B2 (en) 2008-10-16
EP1507547B1 (de) 2011-09-21
CA2488968A1 (en) 2003-11-20
WO2003095476A3 (en) 2004-04-01
IL165066A0 (en) 2005-12-18
CA2488968C (en) 2013-10-29
EP1507547A2 (de) 2005-02-23
WO2003095476A2 (en) 2003-11-20
IL165066A (en) 2011-03-31
AU2003213856A1 (en) 2003-11-11
DK1507547T3 (da) 2012-01-16
JP2006502096A (ja) 2006-01-19
EP1507547A4 (de) 2007-03-14
US20030211095A1 (en) 2003-11-13
ES2373713T3 (es) 2012-02-08

Similar Documents

Publication Publication Date Title
Cubellis et al. Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1.
ATE182336T1 (de) Peptidinhibitoren der urokinaserezeptor-aktivität
PT1178958E (pt) N-cianometilamidas como inibidores de proteases
ES2031826T3 (es) Procedimiento para producir nuevos peptidos activadores del plasminogeno.
HUP0301356A2 (hu) Új, DPPIV-gyel rokon szerin proteáz gének
ATE301198T1 (de) Phospahatasen mit verbesserter phytase-aktivität
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
Wiederanders The function of propeptide domains of cysteine proteinases
ATE525081T1 (de) Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit
Kobayashi et al. Role of activated protein C in facilitating basement membrane invasion by tumor cells
Lijnen et al. Mechanisms of plasminogen activation by mammalian plasminogen activators
EP0290118A3 (de) Fibrinolytisch wirksames Enzym
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
DE69431603T2 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
US7498410B2 (en) Bifunctional variants of recombinant tissue-type plasminogen activator with platelet aggregation inhibitory activity
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
ATE194360T1 (de) Verfahren und mittel für die herstellung von bindungsproteinen für inhibitoren von plasmaproteinasen
DK1379639T3 (da) Muse-glucuronyl-C5-epimerase, DNA der koder for samme, og anvendelser deraf
DE60331414D1 (de) Aggrecanase-1- und -2-peptidsubstrate und verfahren
Coombs et al. Only tissue-type plasminogen activator is secreted by immature bovine Sertoli cell-enriched cultures
Lijnen et al. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator
DE60034434D1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
DE69619539T2 (de) In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1507547

Country of ref document: EP